Ipamorelin Guide

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue. In plain terms, it is designed to stimulate the body's own growth hormone release pathway rather than supply recombinant growth hormone directly. [1][2]

The evidence base is much narrower than online wellness marketing suggests. Published human data include early intravenous pharmacology work in healthy male volunteers and a Phase 2 postoperative ileus trial; the public FDA review found limited evidence of effectiveness for growth hormone deficiency or postoperative ileus and no FDA-approved ipamorelin product. [3][4][5]

This profile is educational only. Trial dosing and registry details are research context, not a dosing protocol, treatment recommendation, or purchasing guide.

Ipamorelin is commonly described as a ghrelin mimetic because it acts through the growth hormone secretagogue receptor pathway. Activation of this pathway can trigger pituitary growth hormone release, which may then affect downstream IGF-1 signaling and related metabolic processes. [1][2][3]

The original pharmacology literature characterized ipamorelin as selective for growth hormone release relative to several earlier growth hormone-releasing peptides. That selectivity is a mechanistic observation, not proof that unsupervised use is safe or clinically useful. [2][5]

A human PK/PD study in healthy male volunteers reported dose-proportional pharmacokinetics after IV infusion, a short terminal half-life, and a single growth hormone pulse that peaked soon after infusion before declining. Those data help explain the research interest, but they do not establish an approved indication. [3]

The 1999 healthy-volunteer PK/PD study examined IV ipamorelin infusion in dose-escalation cohorts. It measured ipamorelin concentrations and growth hormone response rather than patient-centered outcomes such as fat loss, recovery, sleep quality, injury healing, or longevity. [3]

The 2014 Phase 2 postoperative ileus trial was multicenter, randomized, double-blind, and placebo-controlled. It enrolled adults after small or large bowel resection and compared IV ipamorelin with placebo for recovery of gastrointestinal function. [4][6]

That trial did not show statistically significant differences between ipamorelin and placebo in the key or secondary efficacy analyses. The reported median time to first tolerated meal favored ipamorelin numerically, but the result was not statistically significant. [4]

A second Phase 2 ClinicalTrials.gov record, NCT01280344, lists a completed randomized dose-finding study after bowel resection. FDA's review still concluded that available clinical information did not support effectiveness for postoperative ileus or growth hormone deficiency, and that no data supported the proposed subcutaneous route for those conditions. [5][7]

Common online claims for ipamorelin include fat loss, muscle gain, recovery, sleep improvement, anti-aging, and general wellness. Those claims usually extrapolate from growth hormone biology rather than from robust ipamorelin outcome trials in the claimed use cases. [5]

Human evidence does show that ipamorelin can stimulate growth hormone release under studied IV conditions. It does not show that consumer-market injectable products produce reliable body-composition, recovery, sleep, or anti-aging benefits in real-world users. [3][5]

For postoperative ileus, the strongest published clinical trial did not meet its efficacy endpoints. For growth hormone deficiency, FDA noted that professional society guidelines reviewed in its briefing did not discuss ipamorelin for diagnosis or treatment, while FDA-approved alternatives exist for relevant conditions. [4][5]

In the published Phase 2 postoperative ileus study, treatment-emergent adverse events were common in both groups, which is expected in a post-surgical population. The authors reported that ipamorelin was well tolerated in that study, but efficacy was not demonstrated. [4]

FDA's compounding review is more cautious. It identified adverse events reported in clinical study subjects who received IV ipamorelin, including hypokalemia, insomnia, hyperglycemia, nausea, vomiting, abdominal distention, and death; FDA also stated it was unclear whether the two deaths were related to ipamorelin. [5]

FDA also raised concerns about the GH/IGF-1 axis and the possibility of risks similar to approved products that stimulate growth hormone release, including glucose intolerance and diabetes mellitus. Those are not proven outcomes for every ipamorelin exposure, but they are relevant safety questions. [5]

A separate FDA safety-risk page states that compounded drugs containing ipamorelin acetate may pose immunogenicity risk for some routes because of aggregation or peptide-related impurities, and that FDA lacked sufficient information for certain injectable routes. [8]

There is no FDA-approved ipamorelin label with consumer storage instructions. That matters because official storage, beyond-use dating, route, concentration, sterility, endotoxin limits, and handling instructions normally come from regulated labeling or validated pharmacy documentation. [5][8]

FDA's 2024 briefing cited literature suggesting ipamorelin free base was expected to be stable below -18 C and ipamorelin acetate below -20 C, but the same briefing emphasized missing public data on impurities, aggregates, bacterial endotoxins, and product-specific characterization. [5]

For an educational profile, the practical limit is simple: do not treat vendor storage claims, vial labels, or research-use disclaimers as proof of identity, sterility, purity, safety, or clinical appropriateness. [5][8]

References below prioritize official FDA materials, ClinicalTrials.gov records, PubMed-indexed clinical literature, and primary pharmacology literature. Regulatory pages were checked on May 23, 2026.